This study is conducted in Japan. The aim of this observational study is to collect information about the safety and efficacy of Norditropin® long-term treatment of growth hormone deficiency in adults.
Study Type
OBSERVATIONAL
Enrollment
387
Norditropin® (somatropin) prescribed at the discretion of the physician according to normal clinical practice. Safety and effectiveness data is recorded by the physician, and a Quality of Life form is completed by the patient, at visits 1 to 5.
Unnamed facility
Tokyo, Japan
Number and type of suspected serious adverse drug reactions (SADRs) during the study period
Time frame: after 5 years
Number of impaired glucose tolerance events during the study period
Time frame: evaluated after 3 months, 6 months, 1 year and between 2-5 years
Number of other types of adverse events (AEs) during the study period
Time frame: evaluated after 3 months, 6 months, 1 year and between 2-5 years
Effects on body composition (body fat percentage, lean body weight mass, bone density, bone mineral density)
Time frame: evaluated after 3 months, 6 months, 1 year and between 2-5 years
Effects of insulin-like growth factor-1 (IGF-I) levels
Time frame: evaluated after 3 months, 6 months, 1 year and between 2-5 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.